Pancreatic Cancer Research

ResearcherUniversity Medical Center UtrechtActive in the last 2 years

Marcel den Dulk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6161-161X; OpenAlex author ID A5064664373. Sources: ClinicalTrials.gov.

Their work

Papers
21
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
93
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 7 papers, 1 trial · 2025: 4 papers · 2026: 5 papers

Papers 21

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  3. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  4. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  5. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  6. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  7. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  8. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  9. Computer-Aided Decision Support and 3D Models in Pancreatic Cancer Surgery: A Pilot Study. Co-author DOI 10.3390/jcm14051567↗
  10. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  11. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  12. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  13. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  14. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  15. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  16. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  17. Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients. Co-author DOI 10.1002/jso.26670↗
  18. Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. Co-author DOI 10.1038/s41388-020-01578-4↗
  19. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  20. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. Co-author DOI 10.1002/bjs.11093↗
  21. Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer. Co-author DOI 10.1002/jcsm.12419↗

Trials 1

  1. Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas Principal investigator NCT05851534↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bas Groot Koerkamp · 8 shared papers, 2024–2026 · strength 1.37
  2. Ignace H. J. T. de Hingh · 8 shared papers, 2024–2026 · strength 1.37
  3. Marc G. Besselink · 8 shared papers, 2024–2026 · strength 1.37
  4. Izaak Quintus Molenaar · 7 shared papers, 2024–2026 · strength 1.18
  5. Hjalmar C. van Santvoort · 7 shared papers, 2024–2026 · strength 1.18
  6. Casper H.J. van Eijck · 7 shared papers, 2024–2026 · strength 1.18
  7. Sebastiaan Festen · 6 shared papers, 2024–2026 · strength 1.01
  8. Martijn W.J. Stommel · 6 shared papers, 2024–2026 · strength 1.01
  9. Lois A. Daamen · 5 shared papers, 2024–2026 · strength 0.88
  10. Thomas F. Stoop · 5 shared papers, 2024–2026 · strength 0.85
  11. Freek D. Daams · 5 shared papers, 2024–2026 · strength 0.81
  12. Gijs A. Patijn · 5 shared papers, 2024–2026 · strength 0.79
  13. Johanna W. Wilmink · 4 shared papers, 2024–2026 · strength 0.70
  14. Maarten W. Nijkamp · 5 shared papers, 2019–2026 · strength 0.67
  15. J. Sven D. Mieog · 4 shared papers, 2024–2026 · strength 0.66
  16. Geert Kazemier M · 4 shared papers, 2024–2026 · strength 0.66
  17. Vincent Erwin de Meijer · 3 shared papers, 2024–2026 · strength 0.52
  18. Nabiha Akhlaq Mughal · 3 shared papers, 2024–2026 · strength 0.48
  19. Thijs J. Schouten · 3 shared papers, 2024–2026 · strength 0.48
  20. Omar Mahmud · 3 shared papers, 2024–2026 · strength 0.48
  21. Ingmar Florin Rompen · 3 shared papers, 2024–2026 · strength 0.48
  22. Kelly J. Lafaro · 3 shared papers, 2024–2026 · strength 0.48
  23. Richard Andrew Burkhart · 3 shared papers, 2024–2026 · strength 0.48
  24. Joseph R. Habib · 3 shared papers, 2024–2026 · strength 0.48
  25. Iris W.J.M. van Goor · 3 shared papers, 2024–2026 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.